GNS Share Price Performance
UK£24.70
7.52 (43.77%)
33.5% overvalued intrinsic discount
UK£18.50
Fair Value
Price UK£24.70
AnalystLowTarget UK£18.50
AnalystHighTarget UK£32.00
AnalystConsensusTarget UK£27.97
Fair ValueUK£18.79
Share Pricen/a
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
GNS Community Narratives
AN
Fair Value UK£18.79 31.4% overvalued intrinsic discount
Regulatory Pressures And Plant-Based Trends Will Erode Future Profitability
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value UK£35 29.4% undervalued intrinsic discount
Growing Global Protein Demand Will Accelerate Livestock Genetics
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value UK£27.97 11.7% undervalued intrinsic discount
FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Growing Global Protein Demand Will Accelerate Livestock Genetics
Key Takeaways Faster-than-expected regulatory progress and strategic partnerships position Genus for significant revenue and margin expansion, especially in the Chinese market. Leadership in advanced genetics and deepening presence in emerging markets strengthen Genus' premium pricing and future growth opportunities.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
UK£35
29.4% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
6.16% p.a.
Profit Margin
10.96%
Future PE
32.07x
Share price in 2028
UK£42.66
FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream
Key Takeaways Growth in the porcine division and strategic partnerships in China are expected to enhance Genus's revenue and earnings. Expansion in the bovine segment through acquisitions and programs like VAP is projected to improve profit margins and financial stability.Read more
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
UK£27.97
11.7% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
4.92% p.a.
Profit Margin
8.73%
Future PE
33.33x
Share price in 2028
UK£34.09
Regulatory Pressures And Plant-Based Trends Will Erode Future Profitability
Key Takeaways Structural shifts towards alternative proteins and increased scrutiny on animal genetics threaten Genus's market relevance, revenue growth, and long-term earnings stability. Heavy R&D dependence and complex regulation expose Genus to margin compression, strained cash flows, and volatile profitability amid rising global compliance costs.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
UK£18.79
31.4% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
4.02% p.a.
Profit Margin
7.08%
Future PE
27.95x
Share price in 2028
UK£22.72
Recently Updated Narratives
AN
FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream
Fair Value: UK£27.97 11.7% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Pressures And Plant-Based Trends Will Erode Future Profitability
Fair Value: UK£18.79 31.4% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Growing Global Protein Demand Will Accelerate Livestock Genetics
Fair Value: UK£35 29.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Genus plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 26, 2026
- 0.29
- 40.19%
- 2.87%
- 46.0%
About GNS
- Founded
- 1994
- Employees
- 3190
- CEO
- WebsiteView website
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as technical services and advice under the PIC brand. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
